J&J discontinues dengue drug study after changes in R&D portfolio
Tweet
Share
E-mail
FILE PHOTO: The logo of healthcare company Johnson & Johnson is seen in front of an office building in Zug, Switzerland December 1, 2021. REUTERS/Arnd Wiegmann/File Photo
(Reuters) - Johnson & Johnson said on Friday it will discontinue a mid-stage field study of its experimental pill for prevention of dengue as the drugmaker reprioritized its communicable diseases R&D portfolio.
In a separate emailed statement, J&J also said it will also "explore opportunities to advance the clinical development of mosnodenvir outside the company, so that others may build on our research."
No safety issues were identified for the drug, mosnodenvir, the company said.
Six of 10 participants on the drug showed no detectable dengue virus in their blood after being injected with a type of the pathogen, according to data that was presented by J&J in October last year from another mid-stage study.
J&J said that efficacy data from the field study will be available once the final data analyses are complete.
The drug works by blocking the action of two viral proteins, preventing the dengue virus from making copies of itself.
Dengue fever, while often asymptomatic, is also known as "break bone fever" for the severity of the joint pain and spasms that some patients experience.
About half of the world's population is at risk of mosquito-borne dengue disease with an estimated 100 million to 400 million infections occurring each year, according to the World Health Organization.
The company is also developing a vaccine against a bacteria that causes urinary tract infections, bloodstream infections, and pneumonias, and testing approved drugs Cabenuva and Edurant in adolescent and pediatric HIV patients, respectively.
(Reporting by Puyaan Singh in Bengaluru; Editing by Shounak Dasgupta and Leroy Leo)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) st
- Monzo in talks on sale to Nubank at about £10 billion valuation, Sky News reports
- DePuy Synthes Showcases Next-Generation Trauma Innovations at OTA 2026
Create E-mail Alert Related Categories
ReutersSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
